Homestead Advisers Corp Decreases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Homestead Advisers Corp lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 40.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,250 shares of the company’s stock after selling 8,200 shares during the quarter. Homestead Advisers Corp’s holdings in Medpace were worth $4,070,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace during the fourth quarter valued at approximately $31,000. Stone House Investment Management LLC purchased a new position in shares of Medpace in the third quarter valued at approximately $33,000. Jones Financial Companies Lllp boosted its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares during the last quarter. Finally, Lindbrook Capital LLC raised its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent research reports. Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research note on Monday. Finally, Leerink Partners started coverage on shares of Medpace in a research note on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $376.30.

Medpace Stock Down 2.1 %

NASDAQ:MEDP opened at $317.65 on Thursday. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock’s fifty day moving average is $336.81 and its two-hundred day moving average is $339.41. The company has a market capitalization of $9.68 billion, a P/E ratio of 25.15, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.